menu
    • menu
    [{"orgOrder":0,"company":"Uni-Pharma SA","sponsor":"Attikon Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GREECE","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uni-Pharma SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uni-Pharma SA \/ Attikon Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Uni-Pharma SA \/ Attikon Hospital"},{"orgOrder":0,"company":"M. Medici","sponsor":"ZonMw | ACE Pharmaceuticals BV","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"M. Medici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M. Medici \/ ZonMw | ACE Pharmaceuticals BV","highestDevelopmentStatusID":"10","companyTruncated":"M. Medici \/ ZonMw | ACE Pharmaceuticals BV"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Ipe, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ipe, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipe, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipe, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Ipe, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipe, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipe, LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipe, LLC \/ Undisclosed"},{"orgOrder":0,"company":"National Cardiovascular Center Harapan Kita Hospital","sponsor":"CRDF Global | Osypka Medical | Dalim BioTech","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDONESIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"National Cardiovascular Center Harapan Kita Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cardiovascular Center Harapan Kita Hospital \/ CRDF Global | Osypka Medical | Dalim BioTech","highestDevelopmentStatusID":"10","companyTruncated":"National Cardiovascular Center Harapan Kita Hospital \/ CRDF Global | Osypka Medical | Dalim BioTech"},{"orgOrder":0,"company":"Musli Thyropeutics Ltd","sponsor":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Musli Thyropeutics Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Musli Thyropeutics Ltd \/ Tel Aviv Sourasky Medical Center (Ichilov Hospital)","highestDevelopmentStatusID":"8","companyTruncated":"Musli Thyropeutics Ltd \/ Tel Aviv Sourasky Medical Center (Ichilov Hospital)"}]

    Find Clinical Drug Pipeline Developments & Deals for Liothyronine

    Menu

    Liothyronine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            M. Medici

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            M. Medici

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : ZonMw | ACE Pharmaceuticals BV

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

                            Details : Liothyronine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypothyroidism, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 12, 2023

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : ZonMw | ACE Pharmaceuticals BV

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zydus Lifesciences

                            India arrow
                            OTS 2025
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Cadila Receives Final Approval from USFDA for Liothyronine Sodium Tablets

                            Details : Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg, and 50 mcg (US RLD: Cytom...

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 23, 2021

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Uni-Pharma SA

                            Greece arrow
                            OTS 2025
                            Not Confirmed

                            Uni-Pharma SA

                            Greece arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Attikon Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection

                            Details : Liothyronine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lung Diseases.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            April 16, 2020

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Attikon Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Musli Thyropeutics Ltd

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Musli Thyropeutics Ltd

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Tel Aviv Sourasky Medical Center (Ichilov Hospital)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

                            Details : Triiodothyronine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2016

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Tel Aviv Sourasky Medical Center (Ichilov Hospital)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            National Cardiovascular Center Harapan Kita Hospital

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            National Cardiovascular Center Harapan Kita Hospital

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : CRDF Global | Osypka Medical | Dalim BioTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia

                            Details : Triiodothyronine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postoperative Complications.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 13, 2015

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : CRDF Global | Osypka Medical | Dalim BioTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ipe, LLC

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ipe, LLC

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of T3 Therapy in Patients With Hypothyroidism

                            Details : Liothyronine Sodium is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypothyroidism.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            February 27, 2013

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ipe, LLC

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ipe, LLC

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects

                            Details : Liothyronine Sodium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            April 20, 2012

                            Lead Product(s) : Liothyronine Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth